Search

Your search keyword '"Kim, K.B."' showing total 500 results
Start Over Author "Kim, K.B."
500 results on '"Kim, K.B."'

9. Occurrence of Gastrointestinal Adverse Events Upon GLP-1 Receptor Agonist Initiation With Concomitant Metformin Use: A Post Hoc Analysis of LEADER, STEP 2, SUSTAIN-6, and PIONEER 6.

Author

Klein, Klara R., Clemmensen, Kim K.B., Fong, Edwin, Olsen, Søren, Abrahamsen, Trine, and Lingvay, Ildiko

Subjects
*GLUCAGON-like peptide-1 agonists, *GLUCAGON-like peptide 1, *METFORMIN, *TYPE 2 diabetes, *PRODUCT elimination
Abstract

OBJECTIVE: To assess the impact of concomitant metformin use on gastrointestinal adverse events during the initiation and titration of a glucagon-like peptide 1 receptor agonist (GLP-1RA). RESEARCH DESIGN AND METHODS: Using data from four clinical trials of liraglutide and semaglutide (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results [LEADER], Semaglutide Treatment Effect in People with Obesity [STEP 2], Trial to Evaluate Cardiovascular and Other Long-Term Outcomes With Semaglutide in Subjects With Type 2 Diabetes [SUSTAIN-6], and Peptide Innovation for Early Diabetes Treatment [PIONEER] 6), we compared the incidence of gastrointestinal adverse events during GLP-1RA initiation and titration in participants with and without concomitant metformin use. RESULTS: Of 16,996 participants, 12,928 (76%) were treated with metformin. Concomitant metformin use did not increase the percentage of participants who developed gastrointestinal adverse events or their severity during the observation window. Among participants experiencing gastrointestinal adverse events, metformin use did not increase study product discontinuation. Within treatment arms (GLP-1RA and placebo), a numerically higher percentage of metformin nonusers experienced gastrointestinal adverse events and discontinued the study product compared with metformin users. CONCLUSIONS: Concomitant metformin use does not increase occurrence of gastrointestinal symptoms during GLP-1RA initiation or impact GLP-1RA discontinuation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Erratum:Role of fasting duration and weekday in incretin and glucose regulation

Author

Clemmensen, Kim K.B., Quist, Jonas S., Vistisen, Dorte, Witte, Daniel R., Jonsson, Anna, Pedersen, Oluf, Hansen, Torben, Holst, Jens J., Lauritzen, Torsten, Jørgensen, Marit E., Torekov, Signe, and Færch, Kristine

Abstract

The authors and journal apologise for errors in the above paper, which appeared in volume 9 part 4, pages 279-288. The errors relate to three values given in Table 2 on page 283. The value for Unadjusted upper 95% CI of 120 min plasma glucose should be 3.0, not 3.9, the value for Adjusted Estimate of Fasting plasma glucagon should be 0.0 not 0.3, and the value for Unadjusted Estimate of 30 min plasma GLP-1 should be -0.5 not -1.5. These errors do not affect the results or conclusions. The correct Table 2 is given in full below

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results